Cargando…
Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies
Although a raised body mass index (BMI) is associated with increased risk of colorectal cancer (CRC) and recurrence after adjuvant treatment, data in the metastatic setting is limited. We compared overall survival (OS) across BMI groups for metastatic CRC, and specifically examined the effect of BMI...
Autores principales: | Patel, Gargi S, Ullah, Shahid, Beeke, Carol, Hakendorf, Paul, Padbury, Robert, Price, Timothy J, Karapetis, Christos S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618617/ https://www.ncbi.nlm.nih.gov/pubmed/26211512 http://dx.doi.org/10.1002/cam4.490 |
Ejemplares similares
-
The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy
por: Yuan, Meiqin, et al.
Publicado: (2022) -
Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
por: Saif, Muhammad Wasif
Publicado: (2013) -
mCRC: rasante Weiterentwicklung zielgerichteter Therapien
por: Arnheim, Katharina
Publicado: (2022) -
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012) -
Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
por: Schulz, Martin S., et al.
Publicado: (2022)